Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06743649 Phase 1 Study in Healthy Adults
NCT02151617Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06743649 in gout and hyperuricemia (5 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration up to 14 days, Area Under the Curve from Time Zero to end of dosing interval up to 14 days and 5 more. Started Jun 2014; status: completed.
02
Drugs
PF-06743649
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02151617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151617.